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Abstract
Background: Human rotaviruses are the main cause of severe gastroenteritis in children and are responsible for
over 500 000 deaths annually. There are two live rotavirus vaccines currently available, one based on human
rotavirus serotype G1P[8], and the other a G1-G4 P[8] pentavalent vaccine. However, the recent emergence of the
G9 and other novel rotavirus serotypes in Africa and Asia has prompted fears that current vaccines might not be
fully effective against these new varieties.
Results: We report an effort to develop an affordable candidate rotavirus vaccine against the new emerging G9P[6]
(RVA/Human-wt/ZAF/GR10924/1999/G9P[6]) strain. The vaccine is based on virus-like particles which are both highly
immunogenic and safe. The vaccine candidate was produced in Nicotiana benthamiana by transient expression, as
plants allow rapid production of antigens at lower costs, without the risk of contamination by animal pathogens.
Western blot analysis of plant extracts confirmed the successful expression of two rotavirus capsid proteins, VP2
and VP6. These proteins assembled into VLPs resembling native rotavirus particles when analysed by transmission
electron microscopy (TEM). Expression of the rotavirus glycoprotein VP7 and the spike protein VP4 was also tried.
However, VP7 expression caused plant wilting during the course of the time trial and expression could never be
detected for either protein. We therefore created three fusion proteins adding the antigenic part of VP4 (VP8*) to
VP6 in an attempt to produce more appropriately immunogenic particles. Fusion protein expression in tobacco
plants was detected by western blot using anti-VP6 and anti-VP4 antibodies, but no regular particles were observed
by TEM, even when co-expressed with VP2.
Conclusion: Our results suggest that the rotavirus proteins produced in N. benthamiana are candidates for a
subunit vaccine specifically for the G9P[6] rotavirus strain. This could be more effective in developing countries, thereby
possibly providing a higher overall efficacy for the existing vaccines. The production of rotavirus proteins in
plants would probably result in lower manufacturing costs, making it more affordable for developing countries.
Further investigation is required to evaluate the immunogenic potential of the VLPs and fusion proteins
created in this study.
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Background
Rotavirus (RV) infection has probably been a problem as
long as humankind has existed, but the connection be-
tween RV as the leading cause of severe diarrhoeal dis-
ease and dehydration in children under the age of five
worldwide was only made in the 1970s [1]. The disease
accounts for one third of hospitalizations for diarrhoea
worldwide and results in over 500 000 child deaths per
year in under 5-year olds, with mortality greatest in
south Asia and sub-Saharan Africa [2–6].
Rotaviruses are non-enveloped viruses in the family
Reoviridae, genus Rotavirus. Virions are triple-layered
and contain a viral genome that consists of 11 segments
of double-stranded RNA (dsRNA). These dsRNAs en-
code six structural proteins (VPs) and six non-structural
proteins (NSPs). The capsid is composed of an inner
VP2 layer, VP6 forming the intermediate capsid, and an
outer layer made of VP7. VP4 forms 60 spikes on the
outer surface of the virus (Fig. 1). The VP7 layer is es-
sential for incorporation of VP4 into particles and for
the virion to be able to infect a cell. The spike protein
VP4 gets cleaved by proteases located in the host intes-
tinal lumen into VP5* and VP8* [7]. VP8* is highly im-
munogenic and has been proven to elicit high levels of
homotypic and heterotypic neutralising antibodies when
injected into mice [8]. The neutralizing epitope of VP8*
was produced in tobacco plants and has shown to confer
protection against bovine rotavirus infection in a mouse
model [9].
Rotaviruses are divided into 7 groups (A-G) and four
subgroups (I, II, I + II and Non I/II) in group A which
are based on the antigenic properties of VP6 [10, 11].
The 2 outer capsid proteins define the dual serotype
classification of the viruses, with VP4 (protease-sensitive)
defining the P serotype, and VP7 (a glycoprotein) the G
serotype [12, 13]. Presently 27 different G-genotypes and
35 P-genotypes have been described, with at least 73 G/P
genotype combinations having been found. More recently
a classification system that encompasses all 11 RV gene
segments has been introduced, and two major genotype
(non-G, non-P) constellations termed Wa-like and DS-1-
like have been identified [13, 14].
Vaccination is the best control measure to protect
against disease, but prior to specific rotavirus vaccine de-
velopment, the most common serotypes occurring in
specific geographic locations need to be determined in
order to develop a broadly effective vaccine. There are
currently two licensed vaccines available on the market:
GlaxoSmithKline’s Rotarix® and Merck’s RotaTeq™. Both
of these vaccines are given orally and consist of of live
attenuated rotavirus that replicates inside the small in-
testine. Rotarix® contains the most commonly occurring
human rotavirus strain globally, G1P[8]. RotaTeq™ con-
sists of a reassortant collection of 5 viruses comprising
10 bovine rotavirus genes and 5 human rotavirus genes,
protecting against the four most prevalent human strains
of rotavirus; namely, G1, G2, G3 and G4 and serotype
P[4] [15]. A study that reviewed the rotavirus strain
types that were found to be circulating in Africa over a
10 year period (1997–2006) revealed that there was an
increase in RV strain diversity in Africa, with the recent
emergence and spread of the G9 serotype [16–18].
Other studies noted the emergence of G2, G8 and G9
rotaviruses and unusual G and P combinations and a
high prevalence of a P[6] VP4 genotype [11, 19]. Emer-
gence of the G9 and novel rotavirus strains in Africa
prompted fears that the current vaccines might not pro-
tect against these new serotypes, and it is thought that
these rotavirus strains need to be taken into account when
developing new or better vaccines against rotavirus.
A clinical trial with Rotarix® (G1P[8]) in 2006–2007
showed that this vaccine had a 49.9 % efficacy in Malawi
and 76.9 % vaccine efficacy in South Africa [20]. The ef-
ficacy of RotaTeq™, the pentavalent rotavirus vaccine,
was also only 64.2 % in the first year of life; overall vac-
cine efficacy against severe rotavirus gastroenteritis was
39 % in developing countries in sub-Saharan Africa, but
higher (68–75 %) in developed countries [21, 22]. The
efficacy against G9 specifically was 49.7 %. The low effi-
cacy of the two rotavirus vaccines in Africa compared to
more developed countries highlights the need to develop
a vaccine that will be region-specific and will include
prevalent G and P genotypes in the vaccine [23, 24]. Ac-
cordingly, in this work we endeavoured to express rota-
virus proteins from the new emerging G9P[6] (RVA/
Human-wt/ZAF/GR10924/1999/G9P[6]) strain which
was recently sequenced and analysed [11, 25].
One disadvantage of live attenuated vaccines remains
viral shedding and gene reassortment [26]. An alternative
Fig. 1 Schematic representation of a rotavirus virion. The virus is
composed of an outer capsid (VP7 and VP4), an intermediate capsid
(VP6), and an inner capsid (VP2). The outer capsid protein VP4 gets
cleaved by proteases located in the host intestinal lumen into VP5*
and VP8*. The average size of a rotavirus particle is 70 nm
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is non-infectious vaccines based on virus-like particles
(VLPs): these contain only the viral capsid proteins, with
no viral genomic material, and mimic the native rotavirus
virion in antigenicity. An important criterion for the use
of VLPs as vaccine candidates is their safety. Rotavirus
VLPs produced in insect cells and yeast have received at-
tention in recent years as alternative vaccine candidates
that are highly immunogenic and safe [27–30].
Plants have recently been utilized as an alternative pro-
duction system which is suited for the rapid production of
antigens at lower costs, and without the risk of contamin-
ation by animal pathogens [31]. Various groups have
expressed rotavirus capsid proteins in plants. Matsumura
(2002) reported bovine rotavirus A VP6 expression in
transgenic potato plants. The protein was purified and im-
munogenicity studies performed: adult mice developed
anti-VP6 antibodies in their sera. However, there was no
evidence of assembly of the VP6 and immune responses
may have been to simple monomers or trimers [32]. Other
workers showed assembly of VP6 expressed in N.
benthamiana via a potato virus X (PVX)-derived vector.
The VP6 formed trimers, assembled around VP2 cores,
and still assembled when fused to the PVX CP, as protein
rods. Once cleaved from PVX CP, the VP6 assembled into
icosahedral VLPs [33]. A more recent study showed the
successful expression of codon-optimized human rota-
virus VP6 in Chenopodium amaranticolor using a Beet
black scorch virus (BBSV)-mediated expression system
with the VP6 gene replacing the CP gene of BBSV. Oral
immunization of female BALB/c mice with the plant
based VP6 protein induced high titres of anti-VP6 muco-
sal IgA and serum IgG [34]. The paper did not mention,
however, whether or not the VP6 proteins assembled into
VLPs. Saldana et al. (2006) successfully expressed VP2 and
VP6 in the cytoplasm of fruits from transgenic tomato
plants [35]. Electron microscopy showed that a small pro-
portion of the particles had assembled into 2/6 VLPs. A
protective immune response was detected in mice; how-
ever, this may have to some extent been contributed by
the non-assembled VPs.
The above studies showed that rotavirus coat proteins
can be expressed in relatively high levels in plants; that
VP2 and VP6 are capable of forming VLPs in plants, and
that these VLPs elicit protective immune responses in
animal models. In this work, we report an effort to ex-
press several rotavirus proteins in plants via transient
agroinfiltration-mediated expression in N. benthamiana
leaves. These proteins could be considered in the future
as candidates for an affordable rotavirus VLP vaccine
against the new emerging G9P[6] strain. We investigated
the effect of intracellular targeting on expression levels
of VP6 by targeting the protein to the ER, apoplastic
spaces, chloroplast or cytosol. We also fused the highly
immunogenic VP8* or the neutralising epitope of VP8*
to VP6 and co-expressed these chimeric proteins to-
gether with VP2. We further determined the ability of
these proteins to form VLPs by electron microscopy.
Results and discussion
Expression of Rotavirus recombinant proteins in tobacco
plants
All rotavirus proteins used for this study derive from the
G9 P[6] strain which is predominant in South Africa and
other sub-Saharan regions [21, 22]. A VLP vaccine tar-
geting this strain would help in alleviating the burden of
disease in countries from this region.
Agrobacterium tumefaciens cultures containing the re-
combinant proteins were co-expressed with or without
the Tomato spotted wilt virus (TSWV) silencing suppres-
sor protein NSs in N.benthamiana to optimise expression
in plant cells. NSs is a RNA silencing suppressor protein
which inhibits the onset of post-transcriptional gene silen-
cing (PTGS) [36]. Leaf discs were harvested at different
time points to determine the optimum day of expression.
In an attempt to boost protein yields, we initially tried
directing proteins to different intracellular compartments
by using several targeting tags. Infiltrating the plants with
Agrobacterium at different optical densities (ODs) was
also done to determine the optimum OD for highest pro-
tein expression.
The intermediate capsid protein VP6 was successfully
expressed using the plant expression vectors from the
pTRA family. The cytoplasm-targeted 40 kDa VP6 was
present from day one of the time trial, with increasing
protein accumulation during the week-long trial (Fig. 2a).
Adding NSs only enhanced cytoplasmic accumulation of
VP6 at day 7. Protein accumulation of VP6 in the chlo-
roplasts occurred between days 1 and 3. In contrast to
cytoplasmic accumulation, addition of NSs had a consid-
erable effect on accumulation in chloroplasts, as no VP6
was observed in its absence. There was also no detect-
able protein at days 5 and 7 (Fig. 2c). The apoplast and
the ER showed best protein accumulation at day 3 of the
time trial and none at all on days 1 and 7. The addition
of NSs increased expression levels in the ER and apo-
plast, especially on day 3 (Fig. 2b,d). The increase in size
of the ER-targeted VP6 is probably due to the additional
SKDEL and 6xHis sequences present in the pTRAkc-ERH
expression vector. VP6 expression was not enhanced by
targeting the protein to intracellular compartments, com-
pared to cytoplasmic accumulation (Fig. 2). These results
corroborate previous studies where VP6 expression was
always higher in the cytoplasm [32, 33].
VP2 containing a His tag could only be detected as a
~100 kDa band at low levels in the cytoplasm at 3 and 5
dpi and when using different ODs of Agrobacterium for
infiltration, and only when co-expressed with the silen-
cing suppressor NSs (Fig. 3). Similar expression levels
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were seen for VP2 targeted to the ER, chloroplasts and
apoplast (data not shown). VP2 expression without a His
tag could not be explored due to lack of antibodies for
detection. Low expression levels of VP2 in comparison
to VP6 have been seen in both plant and insect cell ex-
pression studies [26–29].
Expression of the outer capsid proteins VP7 and VP4
was also attempted as they are essential for virion-like
immunogenicity and complete particle formation. How-
ever, we could never detect expression of either protein
on their own in plants, even when different pTRA ex-
pression vectors were used (data not shown). Intracellu-
lar targeting also did not have an impact on expression.
In addition, plants infiltrated with VP7 exhibited yellow-
ing symptoms from day 1 and proceeded to wilt during
the time trial. Proceeding with the time trial at a lower
temperature of 17 °C in order to reduce the rate of
metabolic processes in the plant, and thereby hopefully
lower toxicity levels of the protein, was also unsuccess-
ful. Co-infiltrating VP7 with VP2 and VP6 at day 3 was
also tried, to see if proteins could be expressed and then




Fig. 2 VP6 accumulation in the cytoplasm, ER, chloroplast and apoplast. Different vectors were used to target VP6 to intracellular compartments:
a pTRAc-VP6 (cytoplasm), b pTRAkc-ERH-VP6 (Endoplasmic Reticulum), c pTRAkc-rbcs-cTP-VP6 (chloroplast targeting) and d pTRAkc-A-VP6
(apoplast). Western blot was performed to access expression levels of rotavirus VP6 protein in plant leaf cell compartments over 7 days. Mouse
anti-rotavirus VP6 antibody (1:5000) was used to probe the membranes. (+) and (−) indicates expression with or without silencing suppressor
NSs, respectively. Arrows indicate the position of VP6 proteins in the various samples analysed (±42 kDa). M – Pre-stained molecular marker,
−ve – plants infiltrated with NSs only
Fig. 3 Analysis of pTRAc-HT-VP2 expression with a silencing suppressor
(NSs) over time and at different Agrobacterium concentrations.
Proteins were detected by western blot using a commercial anti-his
antibody (1:2000). M – Pre-stained molecular marker. Arrow indicates
expected band size (VP2 ± 100 kDa)
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Difficulties in expressing recombinant VP7 have been
previously described for E. coli and eukaryote cell ex-
pression systems, where VP7 was shown to be toxic for
the cells [37, 38]. VP7 contains a natural ER signal se-
quence that retains it on the ER membrane [39]. It has
been suggested that, once in the ER membrane, VP7
causes an increase in the amount of Ca2+ inside the ER
which leads to a disruption in cell Ca2+ homeostasis
[40]. These dysregulations in Ca2+ concentrations could
be responsible for the cytotoxicity and cell death re-
sponses observed when expressing VP7 [41]. Despite
some studies having reported expression of VP7 in
transgenic potatoes and insect cells, it is important to
note that these used simian rotavirus VP7 [42] and hu-
man group A G1 VP7 [43–45], while our work focused
on human rotavirus G9 VP7. Amino acid differences
between the proteins in specific domains could be re-
sponsible for this effect in N. benthamiana. Future stud-
ies should focus on identifying these toxic domains and
altering them without interfering with protein structure
or immunogenicity.
Since VP4 or VP7 could not be expressed in our sys-
tem, we engineered fusion proteins that would incorpor-
ate the highly immunogenic region of VP4 - located in
the VP8* segment - into the structural protein VP6: the
idea was that this could result in a protein that would
assemble into VLPs without the glycoprotein VP7, while
still presenting protective VP4 epitopes. In 2008, Istrate
et al. showed that VP2 fused to VP8* successfully formed
VLPs when expressed in a baculovirus system with VP6
and VP7, and that these particles induced rotavirus-
specific serum IgG and IgA in mice [46].
The whole VP8* encoding sequence was inserted up-
stream of and in-frame with the amino-terminus of the
VP6 ORF to create VP8*/6. VP8*/6 expression was con-
firmed by western blot using a commercial anti-VP6
antibody (1:5000) (Fig. 4a). This resulted in a band at
about 75 kDa which corresponds to the theoretical size
of the fusion protein VP8*/6 (73 kDa) (Fig. 4a). We were
only able to achieve VP8*/6 expression using the binary
plant expression vector pEAQ-HT; previous attempts
using the plasmids of the pTRA family resulted in low
or non-detectable levels of the protein (data not shown).
We also noted the appearance of a band of approxi-
mately 40 kDa after day 5 (Fig. 4a and b): this corre-
sponds exactly to the size of VP6 and was only detected
using anti-VP6 antibodies. We hypothesise that, because
VP8*/6 still contains the original VP4 trypsin cleavage
site, the 40 kDa band corresponds to VP6 that is pro-
duced by cleavage of VP8*/6 by natural trypsin-like
a)
b)
Fig. 4 Expression of the chimeric protein VP8*/6. a Western blot analysis of pEAQ-VP8*/6 expression in N. benthamiana over time at OD600.0,25
and 0,5. b Western blot of plants infiltrated with either VP8*/6 or VP6 reveals a common band of roughly 45 kDa. Proteins were detected using
commercial anti-VP6 antibody (1/5000). M – Pre-stained molecular marker, −ve – plants with infiltration media only. Arrows indicate expected
band size (VP8*/6 ± 73 kDa, VP6 ± 42 kDa)
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proteases present in the leaves of N.benthamiana. A study
using VP8* fused to VP2 also reported some VP2 degrad-
ation of VLPs containing the VP8*-2 fusion protein [47].
In order to increase chances of particle formation and
to prevent protein cleavage, we designed two additional
strategies for rotavirus fusion proteins. The 10 amino
acid epitope situated at amino acid 1–10 of VP8* has
been shown to be highly immunogenic and to elicit spe-
cific neutralizing antibodies in mice when expressed in
E.coli [48]. The VP8* epitope-encoding sequence was
fused by means of PCR to either the amino- or carboxyl
terminus-encoding sequence of the VP6 ORF to produce
VP6/8*N and VP6/8*C respectively. Western blot ana-
lysis using anti-VP6 antibodies confirmed the presence
of both VP6/8*N and -C versions in the cytoplasm of
plant cells (Fig. 5a and b). Curiously, VP6/8*C appeared
to be expressed more rapidly than VP6/8*N, with high-
est expression levels at 3 d.p.i and 7 d.p.i., respectively.
This shows that the positioning of the epitope may have
an impact on protein accumulation.
Since cytoplasmic accumulation was best for both
rotavirus protein expression and extraction efficiency, all
co-expression work was done exclusively with proteins
accumulating in the cytoplasm. VP2 is a scaffolding pro-
tein that is essential in particle formation; therefore, co-
expression of VP2 with VP6, VP8*/6, VP6/8*N and VP6/
8*C was investigated. Co-expressed proteins were de-
tected by western blot with anti-His and anti-VP6 anti-
bodies. All proteins were detected from 3 days post
infiltration (Fig. 6a and b). VP2 expression levels ap-
peared to be higher when co-expressed withVP6 then when
expressed alone: our hypothesis is that VP6 must be provid-
ing protection by assembling around the VP2 core as in nat-
ural virion morphogenesis, and preventing degradation.
To confirm VLP formation, crude extracts of infiltrated
plants were fractionated by sucrose gradient centrifugation.
Crude extracts were centrifuged on 10 to 60 % sucrose gra-
dients and aliquots from each fraction analysed by
immunoblots probed with mouse anti-VP6 and/or mouse
anti-His antibodies (Additional file 1: Figure S1). All VPs
and derivatives were found in the 20–30 % sucrose zone
(data not shown).
Electron microscopy
Transmission electron microscopy was used to analyse
particles formed by single and co-expressed recombinant
proteins. VP6 alone assembled into helical and tubular
structures as previously described [49, 50] (Fig. 7c).
However, when co-expressed with VP2, spherical particles
resembling the natural virions were seen, in both crude
(Fig. 7e) and sucrose gradient-purified preparations
(Additional file 2: Figure S2). The assembly of VP2/6 par-
ticles has been well documented in the insect-cell expres-
sion system [33, 51]. VP2/6 VLPs have been shown to
elicit immune responses that are protective against rota-
virus infections in mice [52, 53], and gnobiotic piglets
[54]. Particles comprised of VP2/6/7 and 2/4/6/7 have also
been expressed in insect cells; these were generally more
immunogenic and prevented rotavirus infections in differ-
ent animal models [55, 56]. However, difficulty in obtain-
ing large quantities of RV-VLPs containing the outer
surface proteins VP4 and VP7 was experienced in nearly
every study. Accordingly, we experimented with creating
fusion proteins based on the structural properties of VP6
and the immunogenicity of VP4.
Unfortunately, despite numerous attempts, no VLPs
were seen by EM for crude or purified extracts of plants
expressing VP8*/6 (Fig. 7d and f), VP6/8*N or VP6/8*C
(data not shown) single and co-expressed with VP2.
Single expression of VP8*/6, VP6/8*N or VP6/8*C only
resulted in the appearance of amorphous protein aggre-
gates when compared with plants infiltrated with infil-
tration media only (negative control). We hypothesise
that both the full VP8*sequence and the smaller VP8*
epitope must be impeding VP6 trimerisation and par-
ticle formation. Even though few studies have been
a) b)
Fig. 5 Analysis of VP6/8*(N/C) expression over time using two different expression vectors, pRIC 3.0 and pTRAc-HT. a VP6/8*C and b VP6/8*N
expression analysis. Proteins were detected by immunoblotting using anti-VP6 (1/5000) R – pRIC 3.0 + VP6/8*. T – pTRAc-HT + VP6/8*. M – Pre-stained
molecular marker, +ve – pTRAc-VP6. –ve – plants with infiltration media only. Arrows indicate expected band size (VP6/8*(N/C) ± 43 kDa, VP6 ± 42 kDa)
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made on the structural impact of fusions with struc-
tural proteins, there have been reports of conform-
ational changes caused by the simple addition of
polyhistidine tags [57, 58]. Moreover, a recent study on
multi-epitope fusions showed that polypeptides with
small differences in sequence still maintained similar
levels of antigenicity, but protein folding and assembly
were drastically affected [59]. Thus, the fusion proteins
created in this study could still be highly immunogenic
even if they do not form VLPs. Animal experiments still
have to be performed to analyse the ability of these
chimeric proteins as single recombinant subunit vac-
cines that are cheaper, safer and adapted to the South
African strain G9[P6].
a) b)
Fig. 6 Co-expression of VP2 with VP6 and VP6/8*(N/C). a Western blot analysis of crude extract of plants co-expressed with VP2 + VP6/8*. b Western
blot of crude extract of plants co-expressed with VP2 + VP6. VP2 appears to be in higher amounts when co-expressed with VP6. Proteins were detected
using anti-VP6 antibody (1/5000) and anti-histidine (1/2000). M – Pre-stained molecular marker, −ve – plants with infiltration media only.
N – VP8* epitope fused to the amino terminus of VP6. C – VP8* epitope fused to the carboxy terminus of VP6. Arrows indicate expected
band size (VP6*/8(N/C) ± 43 kDa, VP2 ± 100 kDa, VP6 ± 42 kDa)
a) b) c)
d) e) f)
Fig. 7 Detection of rotavirus VLPs by transmission electron microscopy. a Negative control, plants infiltrated with infiltration media only. b Live
rotavirus particles (Photo Credit: F.P. Williams, U.S.) (Environmental Protection Agency (EPA), 2013). c VP6. d VP8*/6. e HT-VP2 + VP6.
f HT-VP2 + VP8*/6. Grids were coated with anti-VP6 (1/500). All plants were harvested at 3 dpi. Bars represent 100 nm
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Conclusion
Efforts to help alleviate the burden of rotavirus disease
in sub-Saharan Africa and other developing countries
have increased significantly in recent years. In this study,
we evaluated the possibility of producing rotavirus VLPs
using a plant expression system to produce a vaccine
specifically adapted to the sub-Saharan African regions.
We had partial success in demonstrating the capacity of
the transient plant expression system to express specific
rotavirus proteins. Despite the fact that no VLPs were
observed for our fusion proteins, expression was de-
tected for all chimeric proteins engineered, illustrating
the versatility of plant-based systems. While this work is
preliminary, we believe that it will serve as a solid basis for
future studies on plant-made rotavirus vaccines for Africa.
Methods
Plasmid construction
VP2, VP4, VP6 and VP7 sequences (GenBank accession
No: FJ183354, FJ183356, FJ183358 and FJ183360) from
human rotavirus G9P[6] were plant codon optimised by
Geneart, Germany (GenBank accession No: KT931666,
KT931667, KT931668 and KT931669 respectively) [25].
The DNA was transformed in DH5-α chemically compe-
tent E. coli cells (E. cloni™, Lucigen) as per manufac-
turer’s instructions. DNA was extracted and genes were
transformed into plant expression vectors, pTRAc (cyto-
plasm), pTRAkc-rbcs-cTP (chloroplast targeting), and
pTRAkc-ERH (endoplasmic reticulum targeting) (Kindly
supplied by R. Fischer, Fraunhofer Institute for Molecu-
lar Biology and Applied Ecology, IME, Germany) [60].
VP2, VP4 and VP6 cDNA was digested with NcoI/XhoI
while VP7 was cut with AflIII/XhoI to clone into pTRAc
and pTRAkc-ERH. pTRAc-HT was used for VP2, VP4
and VP7 because no specific antibodies were available;
pTRAc-HT contains a 6Xhis-tag sequence upstream of
the multiple cloning site (MCS), which allows for a
6Xhis-tag attached at the N-terminus of the protein of
interest. For cloning in pTRAkc-ERH, a NotI restriction
enzyme site was added to replace the stop codon of each
the four rotavirus cDNA by PCR amplification utilising
the primers as detailed in Additional file 3: Table S1. An
additional vector, pTRAkc-A (apoplast), was derived
from pTRAkc-ERH by cutting the vector with NcoI and
XhoI thereby removing the histidine tag and the ER
retention signal (SEKDEL) sequence and resulting in
proteins that are targeted to the apoplast. For cloning
into pTRAkc-rbcs-cTP, cDNA and vector were digested
with MluI/XhoI. DNAs were sequenced to verify fidelity
of the PCR reaction.
Fusion protein design
To create VP8*/6, primers were used to introduce by
PCR, a NcoI site at the 3′ end of the VP8* sequence
located in the VP4 gene. VP6 was then cut with NcoI
and ligated to VP8*; recombinant constructs were fur-
ther modified by PCR to include an AgeI site on the 5′
end thus allowing for cloning into the pEAQ-HT vector
(Additional file 3: Table S1) [61]. For VP6/8*N and VP6/
8*C, specially designed primers were used to create the
VP8*epitope on the desired terminus of the VP6 gene
(Additional file 3: Table S1); each primer overlapped
with 18–21 nucleotides of VP6. Forward primers added
a NcoI site upstream of the VP6 whereas a XhoI site was
supplemented on the 3′ end of the gene by the reverse
primers. These sites allowed for cloning into the plant
expression vectors pTRAc and pRIC 3.0. pRIC 3.0 is a
self-replicating vector previously engineered and shown
to increase recombinant protein expression in N.
benthamiana [62].
Agrobacterium tumefaciens GV3101::pMP90RK was
used with rotavirus pTRA-VP and pRIC-VP constructs
whereas A. tumefaciens LBA4404 was used with the
pEAQ-VP constructs. Electrocompetent Agrobacterium
was mixed with 300 ng of recombinant DNA in a
0.1 cm electrogap cuvette (BioRadTM) then electropo-
rated in a GenePulser (BioRad) under the following set-
tings: 1.8 kV, 25 μF and 200 Ώ [63]. Incubation was
allowed for 1 h at 27 °C in 900 μl of LB before plating
on LA plates containing 30 μg/ml kanamycin (kan),
50 μg/ml rifampicin (rif ), 50 μg/ml carbenicillin (carb)
was added to cultures electroporated with pTRA-VP
constructs and rif and kan was added to pEAQ-VP
constructs.
Recombinant Agrobacterium infiltration
Agroinfiltrations were carried out as described in
Maclean et al. 2007 [60]. Briefly A. tumefeciens LBA 4404
(pEAQ-VPs) and A. tumefeciens GV3101(pMP90RK) were
grown in LB with respective antibiotics and then har-
vested and re-suspended in induction media with anti-
biotics (LB, 10 mM 2-(N-morpholino) ethanesulphonic
acid MES, 2 mM MgSO4, 20 μM acetosyringone
pH 5.6), and grown overnight at 27 °C. Overnight cul-
tures were then spun down and resuspended in infiltra-
tion medium (10 mM MES, 10 mM MgCl2, 3 %
sucrose, pH 5.6, 200 μM acetosyringone and sterile
water) to reach the desired OD600 at 22 °C for 2–3 h
[63]. Three week old wild type N. benthamiana plants
were used for agroinfiltration. The VP proteins were
each infiltrated in separate plants either by vacuum in-
filtration of whole plants or injection of recombinant
Agrobacterium into the abaxial air spaces on the ventral
side of plant leaves. Recombinant Agrobacterium was
infiltrated either with or without the silencing suppres-
sor LBA 4404 (pBIN-NSs). One plant was used per
construct over a seven day time trial and each experi-
ment was done in triplicate.
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Protein extraction and detection
Three leaf discs or whole leaves were harvested for each
construct and ground in liquid nitrogen. Ground leaf
matter was re-suspended in 1x sterile PBS containing
Complete Protease Inhibitor (EDTA-free; Roche) at a ra-
tio of 3:1 (buffer volume : plant weight). This was then
centrifuged for 5 min at 25,861 × g and the pellets (plant
leaf matter) discarded. An additional extraction proced-
ure was carried out on the proteins that were targeted to
the apoplast utilising the pTRAkc-A vector. Whole
leaves from each extraction day were vacuum infiltrated
with sterile PBS containing Complete Protease Inhibitor.
Individual plant leaves were suspended in PBS and put
under a vacuum at 100 mbar for 10 min in a vacuum tank.
The leaves were then rolled and placed in spin columns
(similar to Qiagen spin columns) which were placed in
2 ml Eppendorf tubes and centrifuged at 2448 × g for
15 min and the filtrate was collected.
For western blot analysis, extracts were mixed with
5X SDS-PAGE loading buffer (2 % SDS, 0.1 M Tris–
HCl pH 7.5, 20 mM EDTA, 50 % Glycerol, 4 % β-
mercaptoethanol, 0.02 % bromophenol blue) and boiled
for 2 min at 95 °C, 30uL of samples were loaded and
separated on 12 % SDS-PAGE gels and transferred onto
nitrocellulose membrane by semi-dry electroblotting.
VP proteins were detected using mouse anti-rotavirus
VP6 antibody (US Biologicals) (1:5000), mouse anti-
histidine tag antibody (anti-His) (Sigma®) (1:2000),
followed by goat anti-mouse alkaline phosphate conju-
gated antibodies (1:10 000 Sigma).
Sucrose gradient purification of rotavirus VLPs
Plant protein extracts were initially filtered through
miracloth to remove solid plant matter. Sucrose gradi-
ents from 10 to 60 % sucrose were set up in 40 ml
tubes each by creating six layers of 5 ml of sucrose dis-
solved in sterile PBS (pH 7.4). Clarified protein samples
in 5 to 10 ml volumes were then loaded on top of each
gradient column. Ultracentrifugation at 150 000 × g
(SWTi28 swinging bucket rotor, Beckman Coulter) was
carried out at 4 °C for 1 h 30 min. At the end of the
centrifugation, 2 ml fractions were collected from the
bottom of each column by tube puncture. Dot blots
were then performed to determine fractions with pro-
teins of interest. For each fraction, 1 μl of sample was
loaded in a grid on a nitrocellulose membrane, which
was then blocked with BSA blocking buffer. Western
blot analysis was then performed as usual. Proteins
were probed with mouse anti-VP6 antibody (1:5000) for
VP6 or anti-His for VP2 (1:2000).
Electron microscopy
To determine whether expressed proteins assembled
into VLPs, transmission electron microscopy (TEM) of
immuno-trapped particles was performed. Glow dis-
charged carbon/copper grids were placed on 20 μl of
mouse anti-rotavirus VP6 antibody (1:500) for 5 min and
then washed 3 times with sterile distilled water. Grids
were then placed on 10 μl of the protein extracts and left
for 2 min before being washed 3 times again with sterile
distilled water. Finally, grids were floated on 20 μl of 2 %
uranyl acetate for 1 min before viewing under a TEM
(Zeiss 912 OMEGA Energy Filter Transmission Electron
Microscope, University of Cape Town).
For samples isolated from sucrose gradients, the
sucrose first had to be removed by dialysis before
immune-trapping on the copper grids. The sucrose
fractions were placed in 10 000 MW dialysis cassettes
and dialysed in sterile PBS containing 0.4 M NaCl for
4 h before exchanging the buffer and leaving it over-
night at 4 °C with stirring.
Additional files
Additional file 1: Figure S1. Analysis of sucrose density gradient purified
VP2/6. A) Western blot analysis of VP2/6 fractions using mouse anti-VP6
(1:5000) and anti-His (1:2000). B) SDS-PAGE coomassie stained gel of
fractions. -ve – Fraction 16 of plants infiltrated with silencing suppressor only
and sucrose gradient purified. +ve – VP6 expressed in insect cells.
Arrows indicate protein band size. (PPTX 1090 kb)
Additional file 2: Figure S2. Transmission electron micrograph of
sucrose density gradient purified VP2/6 particles. Purified VP2/6 fractions
were pooled together and dialysed in high salt PBS to remove sucrose
before viewing on a transmission electron microscope. Most of the VLPs
remained intact but some appeared to have lost shape probably as a
result of deformation due to the conditions on the EM grid. Samples
were captured with mouse-anti VP6 antibody (1/500). Bar represents
100 nm. (PPTX 1531 kb)
Additional file 3: Table S1. List of primer sequences used for rotavirus
chimeric protein formation. (PPTX 48 kb)
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